Information  X 
Enter a valid email address

Integrated Diag Hdgs (IDHC)

  Print   

Thursday 17 June, 2021

Integrated Diag Hdgs

Final Dividend Resolution - Date Amendments

RNS Number : 2438C
Integrated Diagnostics Holdings PLC
17 June 2021
 

Final Dividend Resolution - Date Amendments

 

17 June 2021

 

(Cairo and London) - Integrated Diagnostics Holdings ("IDH," "the Company" or "the Group"), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan, and Nigeria, announces the following amendments to the dates contained in resolution ten of the 2021 Notice of Annual General Meeting:

 

Resolution 10: To declare a final dividend of US$ 0.049 per Share in respect of the year ended 31 December 2020 to be paid on 23 July 2021 to the holders of Shares on the register of members as at the close of business on 2 July 2021, with an ex-dividend date of 1 July 2021.

 

Amended Resolution 10: To declare a final dividend of US$ 0.049 per Share in respect of the year ended 31 December 2020 to be paid on 29 July 2021 to the holders of Shares on the register of members as at the close of business on 9 July 2021, with an ex-dividend date of 8 July 2021.

 

The dates have been amended to accommodate IDH's Egypt-based shareholders following the successful completion of the Company's dual listing process.

 

Shareholders who have already cast a vote (by Proxy Form) in respect of Resolution 10 should contact the Registrar immediately if they wish to amend or withdraw their vote.

 

-Ends-

 

About Integrated Diagnostics Holdings (IDH)

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 2,000 diagnostics tests. From its base of 483 branches as of 31 March 2021, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern, African, and Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on the EGX since May 2021 (ticker: IDHC.CA). Learn more at idhcorp.com .

 

The person responsible for arranging the release of this announcement is Nancy Fahmy, Investor Relations Director at IDH.

 

Contact

Nancy Fahmy

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 | [email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSFASAWEFSEIM

a d v e r t i s e m e n t